The subcutaneous administration of ASOs targeting MALAT1 effectively inhibited human lung cancer cell proliferation in a mouse xenograft model as well as in A549 lung cancer cells, which showed a great reduction in the MALAT1 expression level and decreased the migration ability in vitro [243]. Here, MALAT1 is linked to lung carcinoma.